ClinicalTrials.gg
CompletedNCT00715208Updated Apr 29, 2013Results posted

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

A Phase 2 interventional study of rituximab and cyclophosphamide in Relapsed Follicular Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-29.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
82nd of 188
55 · median 48
Started
2008
with 14 others
Phase 2
104 of 194
9 open now
Registered
97th of 194
by date

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 82nd largest by enrollment of the 188 interventional ones that give a count, is one of 15 that started in 2008, is one of 104 in phase 2, and was the 97th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.

03

Conditions studied

  • Relapsed Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient 18 years of age or older
  • Pathological diagnosis of follicular lymphoma (any grade) or marginal zone lymphoma. Patients with transformed follicular lymphoma are eligible, provided there has previously been pathologic documentation of follicular lymphoma.
  • Documented relapse or progression following prior antineoplastic therapy
  • At least 1 measurable tumor mass that is greater than 1.5 cm in the long axis and greater than 1.0 cm in the short axis that has not been previously irradiated, or has grown since previous irradiation
  • No evidence of active central nervous system lymphoma
  • performance status (KPS) ≥50 (equivalent to Eastern Cooperative Group Oncology Group [] status ≤2)

Exclusion criteria

Exclusion Criteria:

  • Diagnosed or treated for a other than Non-Hodgkin's Lymphoma (NHL) within 2 years of first dose, or who were previously diagnosed with a malignancy other than NHL and have any radiographic or biochemical marker evidence of malignancy. Patients with prostate cancer who were treated with definitive radiotherapy who have a serum prostate-specific antigen \<1 ng/mL are not excluded. Patients are not excluded if they have had basal cell or squamous cell carcinoma of the skin that was completely resected, or any in situ malignancy that was adequately treated.
  • Received any of the following treatments or procedures outside of the specified timeframes:

    • Prior treatment with VELCADE
    • Prior treatment with a cumulative dose of doxorubicin of more than 100 mg/m2, if assigned to Arm A (VELCADE-R-CAP)
    • Antineoplastic (including unconjugated therapeutic antibodies and toxin immunoconjugates), experimental, or radiation therapy within 3 weeks before Day 1 of Cycle 1
    • Nitrosoureas within 6 weeks before Day 1 of Cycle 1
    • Radioimmunoconjugates within 10 weeks before Day 1 of Cycle 1
    • stem cell transplant within 3 months before Day 1 of Cycle 1, or prior allogeneic stem cell transplant at any time
    • Major surgery within 2 weeks before Day 1 of Cycle 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    VELCADE R-CAP

    VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.

    Drug: rituximab · Drug: cyclophosphamide · Drug: doxorubicin · Drug: VELCADE · Drug: prednisone

  • Experimental
    VELCADE R-CP

    VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.

    Drug: rituximab · Drug: cyclophosphamide · Drug: VELCADE · Drug: prednisone

06

What researchers measure

Primary outcomes

  1. Number of Patients With Complete Response (CR)

    Disappearance of all evidence of disease assessed by computed tomography (CT) and PET (position-emission tomography) according to the revised International Working Group (IWG) Criteria.

    Time frame: 30 weeks

Secondary outcomes

  1. Number of Participants With Overall Response (OR)

    OR = Complete Response (CR) + Partial Response (PR)according to the revised International Working Group (IWG) Criteria. CR is the disappearance of all evidence of disease assessed by CT and PET. PR is the regression of measurable disease and no new sites assessed by CT and PET.

    Time frame: 30 weeks

  2. Percentage of Participants With Progression-free Survival (PFS) at 1 Year

    PFS was defined as the time from the first dose to the date of progressive disease (PD)/relapse or death, whichever comes first. For a participant who had not progressed/relapsed or died, PFS was censored at the last response assessment that was stable disease (failure to attain complete response/partial response or PD or better).

    Time frame: Assessed at at the end of Cycle 2, at end of treatment visit, and every 12± 1 weeks for the first year (4 visits) until PD

  3. Duration of Response

    Time (in months) from the first documentation of a response (CR or partial response \[PR\]) to the date of first documentation of progressive disease or relapse from complete response. CR is defined as disappearance of all evidence of disease assessed by CT or PET; PR is defined as regression of measurable disease and no new sites assessed by CT or PET according to the revised International Working Group (IWG) Criteria.

    Time frame: 2 years

  4. Number of Patients Who Experienced at Least One Serious Adverse Event

    Time frame: From completion of informed consent through 30 days after the last dose of study drug

07

Results

Posted Apr 29, 2013

Participant flow

Participant flow — Overall Study
MilestoneVELCADE R-CAPVELCADE R-CP
Started748
Completed639
Not completed19
Withdrew: Withdrawal by subject11
Withdrew: Adverse event06
Withdrew: Lack of efficacy02

Outcome measures

PrimaryNumber of Patients With Complete Response (CR)

Disappearance of all evidence of disease assessed by computed tomography (CT) and PET (position-emission tomography) according to the revised International Working Group (IWG) Criteria.

Time frame:
30 weeks
Reported as:
Number · participants
Number of Patients With Complete Response (CR)
participantsVELCADE R-CAPVELCADE R-CP
Number of Patients With Complete Response (CR)1 (0 to 36)13
SecondaryNumber of Participants With Overall Response (OR)

OR = Complete Response (CR) + Partial Response (PR)according to the revised International Working Group (IWG) Criteria. CR is the disappearance of all evidence of disease assessed by CT and PET. PR is the regression of measurable disease and no new sites assessed by CT and PET.

Time frame:
30 weeks
Reported as:
Number · participants
Number of Participants With Overall Response (OR)
participantsVELCADE R-CAPVELCADE R-CP
Number of Participants With Overall Response (OR)637
SecondaryPercentage of Participants With Progression-free Survival (PFS) at 1 Year

PFS was defined as the time from the first dose to the date of progressive disease (PD)/relapse or death, whichever comes first. For a participant who had not progressed/relapsed or died, PFS was censored at the last response assessment that was stable disease (failure to attain complete response/partial response or PD or better).

Time frame:
Assessed at at the end of Cycle 2, at end of treatment visit, and every 12± 1 weeks for the first year (4 visits) until PD
Reported as:
Number · percentage of participants
Percentage of Participants With Progression-free Survival (PFS) at 1 Year
percentage of participantsVELCADE R-CAPVELCADE R-CP
Percentage of Participants With Progression-free Survival (PFS) at 1 Year67 (9.4 to —)63 (11.2 to —)
SecondaryDuration of Response

Time (in months) from the first documentation of a response (CR or partial response \[PR\]) to the date of first documentation of progressive disease or relapse from complete response. CR is defined as disappearance of all evidence of disease assessed by CT or PET; PR is defined as regression of measurable disease and no new sites assessed by CT or PET according to the revised International Working Group (IWG) Criteria.

Time frame:
2 years
Reported as:
Median · Months
Duration of Response
MonthsVELCADE R-CAPVELCADE R-CP
Duration of Response—21.9 (9.4 to NA)
SecondaryNumber of Patients Who Experienced at Least One Serious Adverse Event
Time frame:
From completion of informed consent through 30 days after the last dose of study drug
Reported as:
Number · participants
Number of Patients Who Experienced at Least One Serious Adverse Event
participantsVELCADE R-CAPVELCADE R-CP
Number of Patients Who Experienced at Least One Serious Adverse Event212

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VELCADE R-CAP—2/7 (28.6%)7/7 (100%)
VELCADE R-CP—12/48 (25%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventVELCADE R-CAPVELCADE R-CP
Neutropenic sepsisInfections and infestations1/70/48
Oropharyngeal candidiasisInfections and infestations1/70/48
PyrexiaGeneral disorders1/73/48
Febrile neutropeniaBlood and lymphatic system disorders1/71/48
Leukopenia NOSBlood and lymphatic system disorders1/70/48
LymphadenopathyBlood and lymphatic system disorders0/72/48
Blood culture positiveInvestigations0/72/48
Bronchitis NOSInfections and infestations0/71/48
Bronchitis acute NOSInfections and infestations0/71/48
Pneumonia NOSInfections and infestations0/71/48
Most frequent other events
Showing 10 of 73
Most frequent other events
EventVELCADE R-CAPVELCADE R-CP
AlopeciaSkin and subcutaneous tissue disorders4/78/48
RigorsGeneral disorders4/76/48
DysgeusiaNervous system disorders4/71/48
DiarrhoeaGastrointestinal disorders2/724/48
NauseaGastrointestinal disorders3/721/48
ConstipationGastrointestinal disorders3/710/48
StomatitisGastrointestinal disorders3/72/48
DehydrationMetabolism and nutrition disorders3/73/48
AnaemiaBlood and lymphatic system disorders3/78/48
ThrombocytopeniaBlood and lymphatic system disorders3/76/48

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VELCADE R-CAPVELCADE R-CPTotal
<=18 years000
Between 18 and 65 years72734
>=65 years02121
Age Continuous
Age Continuous(years)VELCADE R-CAPVELCADE R-CPTotal
Mean62.9 ± 8.3062.3 ± 11.3962.3 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)VELCADE R-CAPVELCADE R-CPTotal
Female52429
Male22426
Region of Enrollment
Region of Enrollment(participants)VELCADE R-CAPVELCADE R-CPTotal
United States74855
08

Study locations

43 sites
  • Northwest Alabama Center, PC
    Muscle Shoals, Alabama 35661, United States
  • Providence Saint Joseph Medical Center
    Burbank, California 91505, United States
  • Pacific Coast Hematology Oncology Medical Group
    Fountain Valley, California 92708, United States
  • Loma Linda U Cancer Center
    Loma Linda, California 92354, United States
  • Desert Hematology Medical Group, Inc.
    Rancho Mirage, California 92270, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06498, United States
  • Ocala Cancer Institute
    Ocala, Florida 34471, United States
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia 30060, United States
  • Southern Illinois Hematology Oncology
    Centralia, Illinois 62801, United States
  • Alexian Brothers Hospital Network
    Elk Grove Village, Illinois 60007, United States
  • Clintell, Inc.
    Skokie, Illinois 60077, United States
  • Cancer Care Center, Inc.
    New Albany, Indiana 47150, United States
  • Siouxland Hematology Oncology Associates
    Sioux City, Iowa 51101, United States
  • Hutchinson Clinic
    Hutchinson, Kansas 67502, United States
  • Purchase Cancer Group
    Paducah, Kentucky 42001, United States
  • Medical Oncology, LLC
    Baton Rouge, Louisiana 70809, United States
  • St. Joseph Mercy Hospital
    Ann Arbor, Michigan 48106, United States
  • Kalamazoo Hematology and Oncology
    Kalamazoo, Michigan 49048, United States
  • Jackson Oncology Associates, PLLC
    Jackson, Mississippi 39202, United States
  • St. Louis Cancer Care, LLP
    Chesterfield, Missouri 63017, United States
  • Nebraska Hematology-Oncology, PC
    Lincoln, Nebraska 68506, United States
  • Great Plains Regional Medical Center
    North Platte, Nebraska 69101, United States
  • Southern Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Interlakes Foundation
    Rochester, New York 14623, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Oklahoma Oncology and Hematology, PC
    Oklahoma City, Oklahoma 73112, United States
  • Oklahoma Oncology and Hematology, PC
    Tulsa, Oklahoma 74136, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Allegheny-Singer Research Institute
    Pittsburgh, Pennsylvania 15212, United States
  • Western Pennsylvania Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • Landmark Medical Center
    Woonsocket, Rhode Island 02895, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • HOPE Oncology
    Richardson, Texas 75080, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Marshall University
    Huntington, West Virginia 25701, United States
  • West Virginia University Health Science Center
    Morgantown, West Virginia 26505, United States
  • Marshfield Clinic
    Marshfield, Wisconsin 54449, United States
  • Auxilio Cancer Center
    Hato Rey, 00919, Puerto Rico
09

References and documents

Publications

  • Craig M, Hanna WT, Cabanillas F, Chen CS, Esseltine DL, Neuwirth R, O'Connor OA. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2014 Sep;166(6):920-8. doi: 10.1111/bjh.12991. Epub 2014 Jul 9. PubMed 25039282 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Feb 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2008
First posted
Jul 15, 2008
Start
Sep 2008
Primary completionActual
Feb 2011
CompletionActual
Mar 2011
Results first posted
Apr 29, 2013
Last update
Apr 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00715208
Responsible party
Sponsor
First posted
Jul 15, 2008
Start date
Sep 2008
Primary completion
Feb 2011
Completion
Mar 2011
Results posted
Apr 29, 2013
Last update
Apr 29, 2013

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Cyclophosphamide · Bortezomib · Prednisone

Start the discussion